Skip to main
INKT
INKT logo

MiNK Therapeutics (INKT) Stock Forecast & Price Target

MiNK Therapeutics (INKT) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

MiNK Therapeutics Inc. has experienced a significant increase in its stock price, with shares rising over 400% in the past week, indicating strong investor enthusiasm compared to a mere 2% increase in the Nasdaq Biotechnology Index (NBI). The company's innovative approach to iNKT cell therapies offers scalable and cost-effective manufacturing processes, which enhance its potential for widespread use in treating cancer and other immune-mediated diseases. Further positive momentum is anticipated as updates from the Phase 2 gastric trial of agenT-797, expected in late 2025 or early 2026, could provide critical efficacy data that may influence future evaluations of the company’s growth prospects.

Bears say

MiNK Therapeutics Inc faces significant risks that may adversely affect its financial outlook, including potential safety signals and lower-than-expected efficacy from its clinical programs, which could hinder the advancement of its therapies. Additionally, the company may encounter heightened commercial competition and regulatory challenges, further complicating its path to market. Financially, MiNK requires about $55 million in additional financing through 2038, with a limited cash runway extending only into mid-2025, raising concerns about its funding and operational stability.

MiNK Therapeutics (INKT) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of MiNK Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About MiNK Therapeutics (INKT) Forecast

Analysts have given MiNK Therapeutics (INKT) a Strong Buy based on their latest research and market trends.

According to 1 analysts, MiNK Therapeutics (INKT) has a Strong Buy consensus rating as of Nov 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $35, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $35, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

MiNK Therapeutics (INKT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.